To define the prevalence of ERBB2 mutation and gene amplification in urothelial cancer and its association with patient demographic and pathologic features, we analyzed tumor genomic profiling data from an institutional scale, prospective tumor profiling initiative21. Here, ERBB2 is linked to neoplasm.